Introgen Therapeutics News
Most Popular Introgen Therapeutics Story
Introgen 'explores options' after troubled Q3
Austin-based Introgen Therapeutics reported Tuesday that the company had a third-quarter next loss of $6 million, or 14 cents a share, on revenue of $331,000. Not much better than its net loss of... Read more...
Latest Headlines
- November 12, 2008
- September 2, 2008
- April 15, 2008
- September 27, 2007
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
